Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-7.57%||6.47||0.7%||$452.28m|
|GILD||Gilead Sciences, Inc.||-0.76%||67.63||1.0%||$426.45m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.43%||553.24||2.7%||$408.99m|
|XLRN||Acceleron Pharma, Inc.||0.50%||172.94||5.3%||$345.45m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.07%||181.77||1.9%||$259.59m|
|XENE||Xenon Pharmaceuticals, Inc.||2.12%||33.66||0.4%||$178.19m|
|JSPR||Jasper Therapeutics, Inc.||31.57%||16.42||0.0%||$158.53m|
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.